Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

Toxicology and Applied Pharmacology

Volumn 228, Issue 1, 2008, Pages 17-23

  Lee, Jin Kyung ^a   Leslie, Elaine M ^a   Zamek Gliszczynski, Maciej J ^a   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Dexamethasone; Multidrug resistance associated proteins; Sandwich cultured primary rat hepatocytes; Trabectedin

Indexed keywords

BUTHIONINE SULFOXIMINE; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXAMETHASONE; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; TRABECTEDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HEPATOBILIARY SYSTEM; IN VITRO STUDY; LIVER TOXICITY; MALE; MATHEMATICAL COMPUTING; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BLOTTING, WESTERN; BUTHIONINE SULFOXIMINE; CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; DEXAMETHASONE; DIOXOLES; ENZYME INHIBITORS; HEPATITIS, TOXIC; HEPATOCYTES; L-LACTATE DEHYDROGENASE; LIVER; MALE; P-GLYCOPROTEINS; RATS; RATS, WISTAR; TETRAHYDROISOQUINOLINES;

RATTUS; RATTUS NORVEGICUS;

EID: 40849106388     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.11.020     Document Type: Article

References (57)

1. Beumer J.H., Buckle T., Ouwehand M., Franke N.E., Lopez-Lazaro L., Schellens J.H., Beijnen J.H., and van Tellingen O. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest. New Drugs 25 (2007) 1-7
2. Beumer J.H., Rademaker-Lakhai J.M., Rosing H., Hillebrand M.J., Bosch T.M., Lopez-Lazaro L., Schellens J.H., and Beijnen J.H. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemother. Pharmacol. 59 (2007) 825-837
3. Beumer J.H., Rademaker-Lakhai J.M., Rosing H., Lopez-Lazaro L., Beijnen J.H., and Schellens J.H. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Invest. New Drugs 23 (2005) 429-436
4. Blay J.Y., Le Cesne A., Verweij J., Scurr M., Seynaeve C., Bonvalot S., Hogendoorn P., Jimeno J., Evrard V., van Glabbeke M., and Judson I. A phase II study of ET-743/trabectedin (Yondelis) for patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 40 (2004) 1327-1331
5. Brandon E.F., Meijerman I., Klijn J.S., den Arend D., Sparidans R.W., Lazaro L., Beijnen L., and Schellens J.H. In-vitro cytotoxicity of ET-743 (trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 16 (2005) 935-943
6. Brandon E.F., Sparidans R.W., Guijt K.J., Lowenthal S., Meijerman I., Beijnen J.H., and Schellens J.H. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, trabectidin), a novel marine anti-cancer drug. Invest. New Drugs 24 (2006) 3-14
7. Brouwer K.L.R., and Thurman R.G. Isolated perfused liver. Pharm. Biotechnol. 8 (1996) 161-192
8. Cui Y., Konig J., Buchholz J.K., Spring H., Leier I., and Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55 (1999) 929-937
9. Delaloge S., Yovine A., Taamma A., Riofrio M., Brain E., Raymond E., Cottu P., Goldwasser F., Jimeno J., Misset J.L., Marty M., and Cvitkovic E. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J. Clin. Oncol. 19 (2001) 1248-1255
10. Donald S., Verschoyle R.D., Greaves P., Gant T.W., Colombo T., Zaffaroni M., Frapolli R., Zucchetti M., D'Incalci M., Meco D., Riccardi R., Lopez-Lazaro L., Jimeno J., and Gescher A.J. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res. 63 (2003) 5902-5908
11. Donald S., Verschoyle R.D., Greaves P., Orr S., Jimeno J., and Gescher A.J. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother. Pharmacol. 53 (2004) 305-312
12. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., and Meier P.J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69 (2001) 223-231
13. FDA. Drug induced liver toxicity (2007)
14. Funk C., Pantze M., Jehle L., Ponelle C., Scheuermann G., Lazendic M., and Gasser R. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167 (2001) 83-98
15. George J., Goodwin B., Liddle C., Tapner M., and Farrell G.C. Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes. J. Lab. Clin. Med. 129 (1997) 638-648
16. Gradhand U., Lang T., Schaeffeler E., Glaeser H., Tegude H., Klein K., Fritz P., Jedlitschky G., Kroemer H.K., Bachmakov I., Anwald B., Kerb R., Zanger U.M., Eichelbaum M., Schwab M., and Fromm M.F. Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J. 8 (2008) 42-52
17. Griffith O.W., and Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254 (1979) 7558-7560
18. Grosso F., Dileo P., Sanfilippo R., Stacchiotti S., Bertulli R., Piovesan C., Jimeno J., D'Incalci M., Gescher A., and Casali P.G. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur. J. Cancer 42 (2006) 1484-1490
19. Hirohashi T., Suzuki H., Ito K., Ogawa K., Kume K., Shimizu T., and Sugiyama Y. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Mol. Pharmacol. 53 (1998) 1068-1075
20. Hirohashi T., Suzuki H., and Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 274 (1999) 15181-15185
21. Hirohashi T., Suzuki H., Chu X.Y., Tamai I., Tsuji A., and Sugiyama Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J. Pharmacol. Exp. Ther. 292 (2000) 265-270
22. Hoffmaster K.A., Turncliff R.Z., LeCluyse E.L., Kim R.B., Meier P.J., and Brouwer K.L.R. P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm. Res. 21 (2004) 1294-1302
23. Izbicka E., Lawrence R., Raymond E., Eckhardt G., Faircloth G., Jimeno J., Clark G., and Von Hoff D.D. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol. 9 (1998) 981-987
24. Johnson B.M., Zhang P., Schuetz J.D., and Brouwer K.L.R. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab. Dispos. 34 (2006) 556-562
25. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev., Drug Discov. 4 (2005) 489-499
26. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., Kliewer S., Willson T.M., and Edwards P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277 (2002) 2908-2915
27. Kawabe T., Chen Z.S., Wada M., Uchiumi T., Ono M., Akiyama S., and Kuwano M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 456 (1999) 327-331
28. Kiuchi Y., Suzuki H., Hirohashi T., Tyson C.A., and Sugiyama Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 433 (1998) 149-152
29. Konig J., Nies A.T., Cui Y., Leier I., and Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461 (1999) 377-394
30. Laverdiere C., Kolb E.A., Supko J.G., Gorlick R., Meyers P.A., Maki R.G., Wexler L., Demetri G.D., Healey J.H., Huvos A.G., Goorin A.M., Bagatell R., Ruiz-Casado A., Guzman C., Jimeno J., and Harmon D. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98 (2003) 832-840
31. LeCluyse E.L., Bullock P.L., Parkinson A., and Hochman J.H. Cultured rat hepatocytes. Pharm. Biotechnol. 8 (1996) 121-159
32. LeCluyse E., Bullock P., Madan A., Carroll K., and Parkinson A. Influence of extracellular matrix overlay and medium formulation on the induction of cytochrome P-450 2B enzymes in primary cultures of rat hepatocytes. Drug Metab. Dispos. 27 (1999) 909-915
33. +-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321 (2007) 1170-1178
34. Liu X., Brouwer K.L.R., Gan L.S., Brouwer K.R., Stieger B., Meier P.J., Audus K., and LeCluyse L. Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharm. Res. 15 (1998) 1533-1539
35. Liu X., Chism J.P., LeCluyse E.L., Brouwer K.R., and Brouwer K.L.R. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab. Dispos. 27 (1999) 637-644
36. Lu S.C., Cai J., Kuhlenkamp J., Sun W.M., Takikawa H., Takenaka O., Horie T., Yi J., and Kaplowitz N. Alterations in glutathione homeostasis in mutant Eisai hyperbilirubinemic rats. Hepatology 24 (1996) 253-258
37. Luttringer O., Theil F.P., Lave T., Wernli-Kuratli K., Guentert T.W., and de Saizieu A. Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochem. Pharmacol. 64 (2002) 1637-1650
38. - and EHBR rats. Life Sci. 77 (2005) 1106-1115
39. Nies A.T., and Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453 (2007) 643-659
40. Ogawa K., Suzuki H., Hirohashi T., Ishikawa T., Meier P.J., Hirose K., Akizawa T., Yoshioka M., and Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol.: Gastrointest. Liver Physiol. 278 (2000) G438-G446
41. Paulusma C.C., Kool M., Bosma P.J., Scheffer G.L., ter Borg F., Scheper R.J., Tytgat G.N., Borst P., Baas F., and Oude Elferink R.P. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25 (1997) 1539-1542
42. Reid J.M., Kuffel M.J., Ruben S.L., Morales J.J., Rinehart K.L., Squillace D.P., and Ames M.M. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin. Cancer Res. 8 (2002) 2952-2962
43. Reid G., Wielinga P., Zelcer N., van der Heijden I., Kuil A., de Haas M., Wijnholds J., and Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9244-9249
44. Rius M., Nies A.T., Hummel-Eisenbeiss J., Jedlitschky G., and Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38 (2003) 374-384
45. Ryan D.P., Supko J.G., Eder J.P., Seiden M.V., Demetri G., Lynch T.J., Fischman A.J., Davis J., Jimeno J., and Clark J.W. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res. 7 (2001) 231-242
46. Sasaki M., Suzuki H., Ito K., Abe T., and Sugiyama Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem. 277 (2002) 6497-6503
47. -) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity. Biochem. Pharmacol. 70 (2005) 1832-1839
48. Sinbandhit-Tricot S., Cillard J., Chevanne M., Morel I., Cillard P., and Sergent O. Glutathione depletion increases nitric oxide-induced oxidative stress in primary rat hepatocyte cultures: involvement of low-molecular-weight iron. Free Radic. Biol. Med. 34 (2003) 1283-1294
49. Taamma A., Misset J.L., Riofrio M., Guzman C., Brain E., Lopez Lazaro L., Rosing H., Jimeno J.M., and Cvitkovic E. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 19 (2001) 1256-1265
50. Tian Q., Zhang J., Chan S.Y., Tan T.M., Duan W., Huang M., Zhu Y.Z., Chan E., Yu Q., Nie Y.Q., Ho P.C., Li Q., Ng K.Y., Yang H.Y., Wei H., Bian J.S., and Zhou S.F. Topotecan is a substrate for multidrug resistance associated protein 4. Curr. Drug Metab. 7 (2006) 105-118
51. Turncliff R.Z., Meier P.J., and Brouwer K.L.R. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 32 (2004) 834-839
52. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., and Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13 (2002) 595-603
53. Westley I.S., Brogan L.R., Morris R.G., Evans A.M., and Sallustio B.C. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab. Dispos. 34 (2006) 261-266
54. Xiong H., Turner K.C., Ward E.S., Jansen P.L., and Brouwer K.L.R. Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J. Pharmacol. Exp. Ther. 295 (2000) 512-518
55. Yovine A., Riofrio M., Blay J.Y., Brain E., Alexandre J., Kahatt C., Taamma A., Jimeno J., Martin C., Salhi Y., Cvitkovic E., and Misset J.L. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22 (2004) 890-899
56. Zamek-Gliszczynski M.J., Hoffmaster K.A., Humphreys J.E., Tian X., Nezasa K., and Brouwer K.L.R. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J. Pharmacol. Exp. Ther. 319 (2006) 459-467
57. Zelek L., Yovine A., Brain E., Turpin F., Taamma A., Riofrio M., Spielmann M., Jimeno J., and Misset J.L. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br. J. Cancer 94 (2006) 1610-1614